Statin-associated psychiatric adverse events: A case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting

Drug Safety

Volumn 31, Issue 12, 2008, Pages 1115-1123

  Tuccori, Marco ^a,b   Lapi, Francesco ^b,c,d   Testi, Arianna ^b   Coli, Daniela ^b   Moretti, Ugo ^e   Vannacci, Alfredo ^b,c   Motola, Domenico ^f   Salvo, Francesco ^g   Rivolta, Alma Lisa ^h   Blandizzi, Corrado ^a,b   Mugelli, Alessandro ^b,c   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Tuscan Regional Centre of Pharmacovigilance   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Regional Agency for Healthcare Services of Tuscany   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h Lombardy Centre of Pharmacovigilance   (Italy)

Author keywords

Atorvastatin, adverse reactions; Fluvastatin, adverse reactions; HMG CoA reductase inhibitors, adverse reactions; Lovastatin, adverse reactions; Pravastatin, adverse reactions; Psychiatric disorders, drug induced; Rosuvastatin, adverse reactions

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABNORMAL DREAMING; AGGRESSION; AGITATION; AMNESIA; ANOREXIA; ANTISOCIAL BEHAVIOR; ANXIETY; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONFUSION; DATA ANALYSIS; DATA BASE; DEPRESSION; DRUG SAFETY; HALLUCINATION; HUMAN; IMPOTENCE; INSOMNIA; ITALY; LIBIDO DISORDER; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STATISTICAL ANALYSIS; SUICIDE; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; BEHAVIORAL SYMPTOMS; DATABASES, FACTUAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MENTAL DISORDERS; ODDS RATIO; SEX FACTORS;

EID: 56749132525     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002018-200831120-00007     Document Type: Article

References (33)

1. Bays H. Statin safety: an overview and assessment of the data: 2005. Am J Cardiol 2006 Apr 17; 97 (8A): 6C-26C
2. Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006 Apr; 62 (4): 259-65
3. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. Am J Geriatr Pharmacother 2008 Mar; 6 (1): 28-32
4. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implication for the use of lipid-lowering agents. Drug Saf 2007; 30 (3): 195-201
5. Suribhatla S, Dennis MS, Potter JF. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005 Mar 15; 229-230: 147-50
6. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. Q J Med 2004; 97: 229-35
7. Black DM, Lamkin G, Olivera EH, et al. Sleep disturbance and HMG-CoA reductase inhibitors [letter]. JAMA 1990; 264: 1105
8. Sinzinger H, Mayr F, Schmid P, et al. Sleep disturbance and appetite loss after lovastatin [letter]. Lancet 1994; 343: 973
9. Partinen M, Phil S, Strandberg T, et al. Comparison of effect on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol 1994; 73: 876-80
10. Stalenhoef AFH, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolemia: short term efficacy and safety of increasing doses of simvastatin and pravastatin: a doubleblind comparative study. J Intern Med 1993; 234 (1): 77-82
11. Keech AC, Armitage JM, Wallendszus KR, et al. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Br J Clin Pharmacol 1996; 42: 483-90
12. King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003 Dec; 23 (12): 1663-7
13. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21 (6): 767-9
14. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006 Oct; 40 (10): 1880-3
15. Galatti L, Polimeni G, Salvo F, et al. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006 Aug; 26 (8): 1190-2
16. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003 Jul; 23 (7): 871-80
17. Golomb BA. Implications of statin adverse effects in the elderly. Expert Opin Drug Saf 2005 May; 4 (3): 389-97
18. Whitfield JF. Can statins put the brakes on Alzheimer's disease? Expert Opin Investig Drugs 2006 Dec; 15 (12): 1479-85
19. Hand DJ. Principles of data mining. Drug Saf 2007; 30 (7): 621-2
20. The Italian Interregional Group of Pharmacovigilance - Gruppo Interregionale di Farmacovigilanza [online]. Available from URL: http://www.gruppogif.org/index.htm [Accessed 2008 Jan 23]
21. Uppsala Monitoring Centre. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, 2000
22. van Puijenbroek E, Diemont WL, van Grootheest AC. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003; 26 (5): 293-301
23. Carvajal A, Macias D, Sáinz M, et al. HMG-CoA-reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 2006; 29 (2): 143-9
24. de Langen JJ, van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med 2006 Oct; 64 (9): 334-8
25. Engelberg H. Low serum cholesterol and suicide. Lancet 1992 Mar 21; 339 (8795): 727-9
26. Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005 Feb 28; 133 (2-3): 197-203
27. Pariente A, Gregoire F, Fourrier-Regiat A, et al. Impact of safety alert on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10): 891-8
28. Bender R, Lange S. Adjusting for multiple testing: when and how. J Clin Epidemiol 2001; 54: 343-9
29. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007 Jul 19; 5: 20-30
30. Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006; 185: 3-7
31. Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia [letter]. N Engl J Med 1988 Nov 3; 319 (18): 1222
32. Vgontzas AN, Kales A, Bixler EO, et al. Effects of lovastatin and pravastatin on sleep efficency and sleep stages. Clin Pharmacol Ther 1991 Dec; 50 (6): 730-7
33. Ehrenberg BL, Lamon-Fava S, Corbett KE, et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep 1999 Feb 1; 22 (1): 117-21